Rintatolimod
- Generic Name
- Rintatolimod
- Drug Type
- Biotech
- CAS Number
- 38640-92-5
- Unique Ingredient Identifier
- 94325AJ25N
Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer
- Conditions
- Triple -Negative Breast CancerEstrogen Receptor NegativeAnatomic Stage IV Breast Cancer AJCCHER2/Neu NegativeProgesterone Receptor Negative
- Interventions
- Procedure: BiopsyProcedure: Chemokine Modulation TherapyBiological: Recombinant Interferon Alfa-2bBiological: Pembrolizumab
- First Posted Date
- 2018-07-26
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 8
- Registration Number
- NCT03599453
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Celecoxib, Recombinant Interferon Alfa-2b, and Rintatolimod in Treating Patients With Colorectal Cancer Metastatic to the Liver
- Conditions
- Metastatic Carcinoma in the LiverRecurrent Colorectal CarcinomaStage IV Colorectal Cancer AJCC v7Stage IVA Colorectal Cancer AJCC v7Stage IVB Colorectal Cancer AJCC v7
- Interventions
- Other: Laboratory Biomarker AnalysisBiological: Recombinant Interferon Alfa-2b
- First Posted Date
- 2018-01-18
- Last Posted Date
- 2022-03-02
- Lead Sponsor
- Roswell Park Cancer Institute
- Target Recruit Count
- 19
- Registration Number
- NCT03403634
- Locations
- 🇺🇸
Roswell Park Cancer Institute, Buffalo, New York, United States
Vaccine Therapy in Combination With Rintatolimod and/or Sargramostim in Treating Patients With Stage II-IV HER2-Positive Breast Cancer
- Conditions
- Male Breast CancerStage II Breast CancerStage IIIA Breast CancerStage IV Breast CancerStage IIIB Breast CancerRecurrent Breast CancerHER2-positive Breast CancerStage IIIC Breast Cancer
- Interventions
- First Posted Date
- 2011-05-18
- Last Posted Date
- 2020-02-10
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 50
- Registration Number
- NCT01355393
- Locations
- 🇺🇸
Fred Hutchinson Cancer Research Center/University of Washington Cancer Consortium, Seattle, Washington, United States
The Study of the Safety and Efficacy of Ampligen in Chronic Fatigue Syndrome
- Conditions
- Chronic Fatigue SyndromeMyalgic Encephalomyelitis
- First Posted Date
- 2005-09-22
- Last Posted Date
- 2013-04-17
- Lead Sponsor
- AIM ImmunoTech Inc.
- Target Recruit Count
- 234
- Registration Number
- NCT00215800
A Phase I Clinical Trial To Evaluate the Toxicity, Antiviral and Immunomodulatory Effects of a Range of Doses of Ampligen in HIV-Infected Subjects
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 40
- Registration Number
- NCT00000713
- Locations
- 🇺🇸
Univ of Pittsburgh Med School, Pittsburgh, Pennsylvania, United States
A Clinical Trial To Evaluate the Toxicity and Antiviral Effects of a Range of Doses of Ampligen in p24 Antigen Positive HIV-Infected Patients With AIDS or ARC
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2021-11-03
- Target Recruit Count
- 12
- Registration Number
- NCT00000735
- Locations
- 🇺🇸
Milton S Hershey Med Ctr, Hershey, Pennsylvania, United States
🇺🇸George Washington Univ Med Ctr, Washington, District of Columbia, United States
A Study of Atvogen in Healthy Volunteers and HIV-Infected Patients Who Have No Symptoms of Infection
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2012-10-19
- Target Recruit Count
- 20
- Registration Number
- NCT00001000
- Locations
- 🇺🇸
Johns Hopkins Hosp, Baltimore, Maryland, United States
A Multicenter, Double-Blind, Controlled Study to Evaluate Ampligen
- Conditions
- HIV Infections
- First Posted Date
- 2001-08-31
- Last Posted Date
- 2005-06-24
- Lead Sponsor
- HEM Research
- Registration Number
- NCT00002269
- Locations
- 🇺🇸
Miami Veterans Administration Med Ctr, Miami, Florida, United States
🇺🇸Oregon Health Sciences Univ, Portland, Oregon, United States
🇺🇸MCP Hahnemann Univ Hosp, Philadelphia, Pennsylvania, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.